Abbott banks on glucose monitors, new launches to ride out China, currency hit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Abbott Labs (ABT) PT Raised to $140 at BTIG
January 22, 2025 1:54 PM ESTBTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $139.00) while maintaining a Buy rating.
The analyst comments "Abbott reported a Q4 total revenue miss, much of which we attribute to greater Fx headwinds and lower-than-expected COVID testing revenue, and adj. EPS in line with expectations (see our flash note here). In our view, the main message on the call was the positive 2025 outlook, which called for above-consensus organic sales growth, a return to DD adj. EPS growth, and an impressive 150 bps of... More
